Booklet updates: Navigating your care

The following drug updates are listed by booklet title. This information is not found in the current version of these booklets, as these treatments were not FDA approved at the time the books were published.

Stem cell transplantation
Blood and Marrow Stem Cell Transplantation and Blood and Marrow Stem Cell Transplantation Guide

• In April 2023, the Food and Drug Administration (FDA) approved omidubicel-onlv (Omisirge®) for use in adults and pediatric patients 12 years and older with hematologic malignancies who are planned for umbilical cord blood transplantation following myeloablative conditioning to reduce the time to neutrophil recovery and the incidence of infection.
• In August 2022, the Food and Drug Administration (FDA) approved ibrutinib (Imbruvica®) for the treatment of adult and pediatric patients age 1 year and older with chronic graft versus host disease (cGVHD) after failure of one or more lines of systemic therapy.
• In December 2021, the Food and Drug Administration (FDA) approved abatacept (Orencia®) for the prophylaxis (prevention) of acute graft versus host disease (aGVHD), in combination with a calcineurin inhibitor and methotrexate, in adults and pediatric patients 2 years of age and older undergoing hematopoietic stem cell transplantation (HSCT) from a matched or 1 allele-mismatched unrelated donor.
• In November 2021, the Food and Drug Administration (FDA) approved ruxolitinib (Jakafi®) for the treatment of chronic graft-versus-host disease after failure of one or two lines of systemic therapy in adult and pediatric patients 12 years and older.
• In May 2019, the Food and Drug Administration (FDA) approved ruxolitinib (Jakafi®) for the treatment of steroid-refractory acute graft-versus-host disease in adult and pediatric patients 12 years and older.